No abstract available.
Child* ; Humans

No abstract available.
Arthritis* ; Knee*

OBJECTIVE: In many TMD cases, deformed and reduced condyle heads were frequently observed. This study was prepared to compare the dimensions between normal and symptomatic condyles, using MR images. MATERIALS: One hundred and twenty one patients with clinical signs and MRI-confirmed diagnosis of disc displacement were selected for this study. Thirty eight TMJs from nineteen asymptomatic volunteers who had no clinical symptoms and no disc displacement on sagittal and coronal view of MRI, were served as normal. METHODS: Symptomatic condyles were classified according to the severity of the anterior disc displacement. The amount of anterior disc displacement was evaluated at sagittal section, and they were classified into 4 groups as normal(N), little(G0), mild(G1), moderate(G2) and severe displacement(G3). The dimentions of condyle were measured at the 200% magnified view, by digitizing program. All dimensions were compared among each groups on the central section of sagittal and coronal views, and the statistical analysis was performed. RESULTS: The mean value of anteroposterior length of normal condyle was 0.79+/-0.13cm at sagittal section and mediolateral length was 2.12+/-0.22cm on coronal section. The mean value of anteroposterior length of symptomatic condyle was 0.67+/-0.16cm at sagittal section and mediolateral length was 1.97+/-0.28cm on coronal section. CONCLUSIONS: The size of symptomatic condyle was smaller than normal TMJ. The size of condyle was decreased as the amount of the disc displacement was increased. The dimensional change was found on the anterior articular surface of condyle at the mild or moderate disc displacement. And at the case of severe disc displacement, dimensional change was found on the superior articular surface.
Diagnosis ; Head* ; Humans ; Magnetic Resonance Imaging ; Temporomandibular Joint ; Volunteers

No abstract available.
Emergencies* ; Emergency Service, Hospital*

Nose is the most prominent of part of the face and prone to traumas. Therefore posttraumatic deformities are easily seen and play a major effect on the personal impression. Result of clinical analysis of nasal bone fracture that gives general understands and advices of diagnosis and treatment of nasal bone fracture is presented with reports discussed. The author has performed radiologic evaluation, clinical study and statistical analysis in 1488 cases of nasal bone fracture treated in Department of Plastic and Reconstructive Surgery, Inje University Sanggye Paik hospital, from March, 1992 to February, 2002 Most of operation were performed on 5th-10th posttraumatic days(80.7%), and 1040 cases were treated with closed reduction using C-arm. We could obtain satisfactory results using C-arm. In satisfaction rate, 1296 cases(87%) had satisfactory results. The rate of dissatisfaction was high in the patients performed operation after 11th posttraumatic days and who had septal fracture. The author used C-arm during closed reduction of nasal bone fracture and verified the outcomes intraoperatively and were able to get more accurate reduction. With this method, we could obtain satisfactory results cosmetically and functionally. We should follow-up for longer time and we think that further research will be needed in treatment of nasal bone fracture
Congenital Abnormalities ; Diagnosis ; Follow-Up Studies ; Humans ; Nasal Bone* ; Nose ; Plastics ; Retrospective Studies

No abstract available.

No abstract available.

No abstract available.
Bone Marrow* ; Humans

BACKGROUND: Cancer invasion and metastasis require the dissolution of the extracellular matrix in which several proteolytic enzymes are Involved. One of these enzymes is the urokinase - type plasminogen activator(u-PA), and plasminogen activator inhibitors(PAI-1, PAI-2) a]so have a possible role in cancer invasion and metastasis by protection of cancer itself from proteolysis by u-PA. It has been reported that the love]s of u-PA and plasminogen activator inhibitors in various cancer tissues are significantly higher than those in normal tissues and have significant correlations with tumor size and lymph node involvement Here, we measured the concentration of plasma u-PA and PAI- 1 antigens in the patients with lung cancer and compared the concentration of them with histologic types and staging parameters. METHODS: We measured the concentration of plasma u-PA and PAI-1 antigens using commercial ELISA kit in 37 lung cancer patients, 21 benign lung disease patients and 24 age-matched healthy controls, and we compared the concentration of them with histologic types and staging parameters in lung cancer patients. RESULTS: The concentration of u-PA was 1.0α0.3ng/mL in controls, 1.0α0.3ng/mL in benign lung disease patients and 0.9α0.3ng/mL in lung cancer patients. The concentration of PAI-1 was 14.2α6.7ng/mL in controls, 14.9α6.3ng/mL in benign lung disease patients, and 22.1 α9.8ng/mL in lung cancer patients. The concentration of PAI- 1 in lung cancer patients was higher than those of benign lung disease patients and controls. The concentration of u-PA was 0.7α0.4ng/mL in squamous cell carcinoma, 0.8α 0.3ng/mL in adenocarcinoma, 0.9ng/mL in large cell carcinoma, and 1.1α0.7ng/mL in small cell carcinoma. The concert traction of PAI-1 was 22.3α7.2ng/mL in squamous cell carcinoma, 22.6α9.9ng/mL in adenocarcinoma, 42ng/mL in large cell carcinoma, and 16.0α14.2ng/mL in small cell carcinoma. The concentration of u-PA was 0.74ng/mL in stage I, 1.2α0.6ng/mL in stage II, 0.7 α 0.4ng/mL in stage IIIA, 0.7α0.4ng/mL in stage IIIB, and 0.7α0.3ng/mL in stage IV. The concentration of PAI-1 was 21.8ng/mL in stage I, 22.7α8.7ng/mL in stage II, 18.4 α4.9ng/mL in stage IIIA, 25.3α9.0ng/mL in stage IIIB, and 21.5α10.8ng /mL in stage IV. When we divided T stage unto T1-3 and 74, the concentration of u-PA was 0.8α 0.4ng/mL in T1-3 and 0.7α0.4ng/mL in T4, and the concentration of PAI-1 was 17.9α 5.6ng/mL in T1-3 and 26.1α9.1ng/mL in T4. The concentration of PAI-1 in T4 was significantly higher than that in T1-3. The concentration of u-PA was 0.8α 0.4ng/mL in M0 and 0.7α0.3ng/mL in Ml, and the concentration of PAI-1 was 23.6α8.3ng/mL in M0 and 21.5α10.8ng/mL in M1 CONCLUSIONS: The plasma levels of PAI-1 in lung cancer were higher than benign lung disease and control, and the plasma levels of PAI-1 in 74 were significantly higher than T1-3. These findings suggest involvement of PAI-1 with local invasion of lung cancer, but it should be confirmed by the data on comparison with pathological staging and tissue level in lung cancer.
Adenocarcinoma ; Carcinoma, Large Cell ; Carcinoma, Small Cell ; Carcinoma, Squamous Cell ; Enzyme-Linked Immunosorbent Assay ; Extracellular Matrix ; Humans ; Lung Diseases ; Lung Neoplasms* ; Lung* ; Lymph Nodes ; Neoplasm Metastasis ; Peptide Hydrolases ; Plasma* ; Plasminogen ; Plasminogen Activator Inhibitor 1* ; Plasminogen Activators ; Plasminogen Inactivators ; Proteolysis ; Traction ; Urokinase-Type Plasminogen Activator*

Success of skin grafts depends on sufficient immobilization and early intervention for hematoma, seroma, or infection. To stabilize and cover skin grafts with a tie-over technique was used with translucent silicone gel sheet on flat surface. Skin defect was resurfaced with skin grafts. A sterile silicone gel sheet was placed over the skin graft. Gel was fixed to the wound edges with skin sutures. Skin graft healed without any complications. Using silicone gel sheet in skin graft on flat surface is an effective method for stabilization, which also allows direct visualization of the graft designed to inspect hematoma-like complications.
Bandages* ; Early Intervention (Education) ; Hematoma ; Immobilization ; Seroma ; Silicone Gels* ; Skin* ; Sutures ; Transplants* ; Wounds and Injuries